Laboratory-Network Capacity Board Examiner — Clinical Diagnostics

The mandate

Capital proposals use analyser utilisation and annual specimen growth, but urgent mix, batching rules, courier arrival, reagent constraints and repeat testing determine usable capacity. Individual laboratories protect turnaround by referring work, shifting delay and transport exposure elsewhere. The board’s standing question is whether new analysers retire a genuine network constraint or institutionalise fragmented production and hidden clinical risk.

The adviser commits four days monthly: one reviewing operating and clinical evidence, two with laboratory and network leaders, and one preparing or attending the committee. Five committee meetings and six capacity examinations are included. Challenge on an urgent analyser replacement or referral decision will be returned within three business days, never as clinical or laboratory instruction.

The term lasts eight months through approval of the network-capital plan. A two-month extension may be authorised only if an unplanned analyser-platform withdrawal changes the available scenarios. The committee decides after updated conflicts; implementation tracking, vendor negotiation or routine performance review are excluded reasons for renewal.

The examiner has no line authority and carries no executive, clinical or scientific responsibility for specimen acceptance, test validation, result release, referral, quality, staffing, procurement or capital delivery. Management submits the plan; accredited roles retain laboratory decisions; directors allocate investment. The adviser may challenge assumptions and evidence but cannot choose analysers or direct specimen flow.

Work with competing laboratory groups, hospitals, analyser or reagent suppliers, logistics companies, pathology platforms, investors or payers must be disclosed. The scope excludes clinical validation, procurement evaluation, accreditation, result review, laboratory inspection, pricing, referral contracting, incident investigation and any assessment of named scientific or operational leaders.

Why the board wants this voice

The committee sees vendor cases and local capacity plans but lacks a former network operator able to translate specimen-level variability into enterprise choices. Independent scrutiny can distinguish equipment shortage from operating-policy constraint without intruding on accredited clinical and scientific authority. It will further expose referral decisions that improve local turnaround while consuming resilience elsewhere in the network and creating unmeasured clinical delay.

What you will own

• Press management on specimen mix, arrival profile, batching, repeats, maintenance, reagent and specialist-review constraints.
• Test whether proposed capacity survives analyser loss, courier bunching, urgent demand and referral unavailability.
• Challenge utilisation averages that conceal clinically important queues, quality holds or unused narrow capability.
• Examine referral economics across turnaround, transport stability, evidence custody, resilience and retained competence.
• Compare laboratories using common definitions for usable capacity, demand, downtime and verified clinical service.
• Maintain a board ledger of capacity premises, vendor claims, mitigation promises, decision thresholds and outcomes.
• Probe six scenarios spanning analyser failure, reagent shortage, courier loss, contamination event and demand surge.

Candidate qualifications

• Held multi-site clinical laboratory operations or diagnostic-network accountability within an accredited environment.
• Planned capacity using specimen-level mix, clinical priority, analyser reliability and logistics constraints directly.
• Challenged major capital where workflow, batching, maintenance or referral policy was the true binding constraint.
• Understood scientific, clinical, quality and accredited-role boundaries without offering unauthorised laboratory direction.
• Advised boards while preserving accountable management ownership of network investment and service performance.
• Maintained documented continuing professional independence from laboratory operators, hospitals, analyser suppliers, reagent firms and pathology investors.

Non-negotiables

• Available four days monthly for Amsterdam work, five meetings and six capacity examinations.
• Direct accredited laboratory-network operations is required; healthcare finance alone is insufficient.
• Will disclose laboratories, hospitals, vendors, logistics providers, payers, investors and pathology interests.
• Will not validate tests, release results, inspect laboratories, select analysers or direct specimen flow.

1. 49 words maximum. Describe a laboratory capital request where specimen mix disproved headline analyser utilisation.
2. 49 words maximum. Which diagnostics relationships would require disclosure to this committee?
3. 49 words maximum. How would you test network capacity without influencing clinical result decisions?